These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Multiple sclerosis: new treatment trials and emerging therapeutic targets. DeAngelis T; Lublin F Curr Opin Neurol; 2008 Jun; 21(3):261-71. PubMed ID: 18451708 [TBL] [Abstract][Full Text] [Related]
4. Disease-modifying drugs for the early treatment of multiple sclerosis. Flachenecker P Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542 [TBL] [Abstract][Full Text] [Related]
5. Immunopathogenesis and immunotherapeutic approaches in multiple sclerosis. Lim ET; Giovannoni G Expert Rev Neurother; 2005 May; 5(3):379-90. PubMed ID: 15938671 [TBL] [Abstract][Full Text] [Related]
6. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews. Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542 [TBL] [Abstract][Full Text] [Related]
7. [Advances in the treatment of multiple sclerosis?]. Tackenberg B; Himmerich H; Wellek A; Oertel WH; Sommer N MMW Fortschr Med; 2007 May; 149 Suppl 2():51-5. PubMed ID: 17724968 [TBL] [Abstract][Full Text] [Related]
8. Toward the development of rational therapies in multiple sclerosis: what is on the horizon? Hemmer B; Hartung HP Ann Neurol; 2007 Oct; 62(4):314-26. PubMed ID: 17969020 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. Wiendl H; Hohlfeld R BioDrugs; 2002; 16(3):183-200. PubMed ID: 12102646 [TBL] [Abstract][Full Text] [Related]
10. Management of multiple sclerosis: current trials and future options. Noseworthy JH Curr Opin Neurol; 2003 Jun; 16(3):289-97. PubMed ID: 12858064 [TBL] [Abstract][Full Text] [Related]
11. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials. Bates D Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678 [TBL] [Abstract][Full Text] [Related]
12. Getting specific: monoclonal antibodies in multiple sclerosis. Lutterotti A; Martin R Lancet Neurol; 2008 Jun; 7(6):538-47. PubMed ID: 18485317 [TBL] [Abstract][Full Text] [Related]
13. [Pharmacological treatment of multiple sclerosis]. Myhr KM Tidsskr Nor Laegeforen; 2010 Mar; 130(5):490-2. PubMed ID: 20224616 [TBL] [Abstract][Full Text] [Related]